These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 29157861)

  • 1. Hydroxychloroquine as a steroid-sparing agent in an infant with chronic urticaria.
    Iweala OI; Copenhaver C; Wu EY; Moran TP
    Ann Allergy Asthma Immunol; 2018 Jan; 120(1):102-104. PubMed ID: 29157861
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapy of antihistamine-resistant chronic spontaneous urticaria.
    Greiwe J; Bernstein JA
    Expert Rev Clin Immunol; 2017 Apr; 13(4):311-318. PubMed ID: 27744711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiopathic postprandial diarrhea responsive to antihistamines.
    Hassoun Y; Stevenson MR; Bernstein DI
    Ann Allergy Asthma Immunol; 2019 Oct; 123(4):407-409. PubMed ID: 31279076
    [No Abstract]   [Full Text] [Related]  

  • 4. The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria.
    Sanada S; Tanaka T; Kameyoshi Y; Hide M
    Arch Dermatol Res; 2005 Sep; 297(3):134-8. PubMed ID: 16044256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chronic urticaria in childhood : Rational diagnostics and treatment].
    Ott H
    Hautarzt; 2017 Jul; 68(7):571-582. PubMed ID: 28474101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use.
    Khan DA
    J Allergy Clin Immunol Pract; 2013; 1(5):433-440.e1. PubMed ID: 24565613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral monteleukast in urticaria induced by nonsteroidal anti-inflammatory drugs.
    Goel A; Prasad D
    J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1275-6. PubMed ID: 17894732
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of montelukast and fexofenadine for chronic idiopathic urticaria.
    Nettis E; Dambra P; D'Oronzio L; Loria MP; Ferrannini A; Tursi A
    Arch Dermatol; 2001 Jan; 137(1):99-100. PubMed ID: 11176678
    [No Abstract]   [Full Text] [Related]  

  • 9. Author's reply.
    Sil A; Das N
    Indian J Dermatol Venereol Leprol; 2018; 84(1):60-61. PubMed ID: 29271369
    [No Abstract]   [Full Text] [Related]  

  • 10. Pressure challenge test and histopathological inspections for 17 Japanese cases with clinically diagnosed delayed pressure urticaria.
    Morioke S; Takahagi S; Iwamoto K; Shindo H; Mihara S; Kameyoshi Y; Hide M
    Arch Dermatol Res; 2010 Oct; 302(8):613-7. PubMed ID: 20480170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter in response to "Effectiveness and safety of levocetirizine 10 mg versus a combination of levocetirizine 5 mg and montelukast 10 mg in chronic urticaria resistant to levocetirizine 5 mg: A double-blind, randomized, controlled trial" by Sarkar
    Marrouche N; Williams HC
    Indian J Dermatol Venereol Leprol; 2018; 84(1):59-60. PubMed ID: 29271368
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of solar urticaria using antihistamine and leukotriene receptor antagonist combinations tailored to disease severity.
    Levi A; Enk CD
    Photodermatol Photoimmunol Photomed; 2015 Nov; 31(6):302-6. PubMed ID: 26052871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for the Treatment of Recalcitrant Chronic Autoimmune Urticaria.
    Steinweg SA; Gaspari AA
    J Drugs Dermatol; 2015 Dec; 14(12):1387. PubMed ID: 26659929
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and efficacy of cetirizine versus cetirizine plus ranitidine in chronic urticaria: Double-blind randomized placebo-controlled study.
    Guevara-Gutierrez E; Bonilla-Lopez S; Hernández-Arana S; Tlacuilo-Parra A
    J Dermatolog Treat; 2015; 26(6):548-50. PubMed ID: 25886090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results.
    Bagenstose SE; Levin L; Bernstein JA
    J Allergy Clin Immunol; 2004 Jan; 113(1):134-40. PubMed ID: 14713918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urticaria as a first clinical manifestation of COVID-19.
    Veraldi S; Romagnuolo M; Benzecry V
    Eur J Dermatol; 2020 Dec; 30(6):737-738. PubMed ID: 33459263
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of refractory chronic urticaria: current and future therapeutic options.
    Asero R; Tedeschi A; Cugno M
    Am J Clin Dermatol; 2013 Dec; 14(6):481-8. PubMed ID: 24085572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukotriene modifiers in chronic urticaria.
    Bensch G; Borish L
    Ann Allergy Asthma Immunol; 1999 Oct; 83(4):348. PubMed ID: 10541429
    [No Abstract]   [Full Text] [Related]  

  • 19. Fexofenadine: new preparation. Terfenadine, without cardiotoxicity.
    Prescrire Int; 1999 Feb; 8(39):11-3. PubMed ID: 10557567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of telangiectasia macularis eruptiva perstans with montelukast.
    Cengizlier R; Hücümenoğlu S; Ozen A; Tülin Sayli R
    Allergol Immunopathol (Madr); 2009; 37(6):334-6. PubMed ID: 19913347
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.